Dayvigo Side Effects: Incidence Rates Across Clinical Trials

How Lemborexant Works and Why the Side-Effect Profile Differs From Other Sleep Drugs

Lemborexant blocks orexin OX1 and OX2 receptors, the same receptor pair targeted by suvorexant (Belsomra). This mechanism differs from benzodiazepines and Z-drugs, which act at GABA-A receptors. Because lemborexant does not produce global CNS depression, certain classic hypnotic side effects, including anterograde amnesia and rebound insomnia, occur at lower rates. Still, suppressing orexin signaling carries its own set of risks.

The FDA approved lemborexant under NDA 211986 based primarily on data from two Phase 3 randomized controlled trials, SUNRISE-1 and SUNRISE-2. The prescribing information lists the adverse-event incidence rates from those trials as the primary safety reference for clinicians.

Orexin Suppression and Predicted Adverse Events

When orexin activity is reduced at night, sleep-onset latency falls and wake-after-sleep-onset improves. The trade-off is residual receptor blockade into the morning hours, which drives next-day somnolence and psychomotor slowing. The 10 mg dose produces greater receptor occupancy than 5 mg, and that difference maps almost linearly onto the somnolence incidence gap between doses.

Comparison With GABA-Targeting Hypnotics

Unlike zolpidem, lemborexant does not produce clinically significant respiratory depression at approved doses in otherwise healthy adults. A 2023 comparative review in Sleep Medicine Reviews noted that orexin antagonists as a class show lower rates of dependence and tolerance than benzodiazepine receptor agonists, though head-to-head trial data specific to lemborexant vs. Zolpidem remain limited. PubMed: Citrome 2020

SUNRISE-1: Adverse Event Incidence at 30 Days

SUNRISE-1 (NCT02783729) was a 1-month, double-blind, placebo-controlled and active-controlled trial comparing lemborexant 5 mg and 10 mg against placebo in 1,006 adults with insomnia disorder. The primary endpoints were sleep efficiency and wake after sleep onset measured by polysomnography. PubMed: Rosenberg et al. 2019

Somnolence and Fatigue

Somnolence was the most frequently reported treatment-emergent adverse event. In the lemborexant 5 mg arm, 7% of participants reported somnolence vs. 1% on placebo. At 10 mg, that figure rose to 17%. Fatigue followed a similar pattern: 3% (5 mg), 6% (10 mg), and 1% (placebo).

Headache and Nasopharyngitis

Headache occurred in 6% of the 5 mg group, 4% of the 10 mg group, and 5% of placebo recipients. Because headache rates were comparable across groups, it is likely not a drug-attributable effect at meaningful rates. Nasopharyngitis appeared in roughly 3% of all groups, consistent with background incidence.

Discontinuations in SUNRISE-1

Adverse-event-related discontinuations were 3.8% in the 5 mg arm, 5.4% in the 10 mg arm, and 2.1% in placebo. Somnolence and fatigue drove most withdrawals. No deaths occurred during the trial, and serious adverse events were balanced across arms.

SUNRISE-2: Adverse Event Incidence at 12 Months

SUNRISE-2 (NCT02952820) extended the safety observation window to 12 months in 949 adults, making it the largest long-term safety dataset for lemborexant available at the time of FDA approval. PubMed: Kärppä et al. 2020

Somnolence Over Time

At 12 months, somnolence incidence was 10% for 5 mg and 22% for 10 mg vs. 6% for placebo. These rates were higher than the 30-day SUNRISE-1 figures, likely reflecting broader reporting sensitivity over a longer observation window rather than worsening drug effect. Most somnolence events were mild to moderate in severity.

Sleep Paralysis and Cataplexy-Like Events

Sleep paralysis was reported by 1.1% of participants on 5 mg, 2.0% on 10 mg, and 0.2% on placebo in SUNRISE-2. The FDA prescribing label notes that these events "may be associated with hypnagogic or hypnopompic hallucinations." Cataplexy-like events were rare but present: 0% (placebo), 0.4% (5 mg), and 0.7% (10 mg). FDA label NDA 211986

Hallucinations

Hypnagogic and hypnopompic hallucinations occurred in 1.0% of participants on 5 mg and 1.6% on 10 mg, vs. 0.4% on placebo. The FDA considers this a class effect for dual orexin receptor antagonists. Most events were transient and resolved without treatment discontinuation.

Falls and Injury

Falls were reported in 1.9% of the lemborexant 10 mg group over 12 months vs. 0.6% on placebo. This signal is clinically meaningful in older adults. The American Academy of Sleep Medicine 2017 clinical practice guideline for chronic insomnia management recommends caution when prescribing sedating hypnotics to patients with a fall history. AASM guideline

Next-Morning Driving Impairment: A Dedicated Study

The FDA required a dedicated on-road driving study as part of the lemborexant development program. Conducted in 60 healthy adults aged 55 and older, the trial measured standard deviation of lateral position (SDLP), a validated surrogate for impaired driving. At 9 hours post-dose, lemborexant 10 mg produced a statistically significant increase in SDLP compared to placebo (mean difference 2.68 cm, 90% CI 1.26 to 4.10; P<0.01). The 5 mg dose produced a smaller, non-significant SDLP increase at 9 hours. PubMed: Vermeeren et al. 2019

This finding directly informs the prescribing label warning: patients should not drive or operate heavy machinery until they know how lemborexant affects their alertness the next morning.

Age-Stratified Impairment Risk

Older adults showed greater SDLP increases than younger participants at equivalent doses. The FDA prescribing label recommends starting with the 5 mg dose in adults aged 65 and older, reserving 10 mg for patients who tolerate 5 mg but require additional efficacy.

Complex Sleep Behaviors: The FDA Black Box Warning

In April 2020, the FDA added a boxed warning to lemborexant, suvorexant, and zaleplon requiring that all three drugs include language about complex sleep behaviors. These behaviors, including sleepwalking, sleep driving, and other activities performed while not fully awake, have resulted in serious injuries and deaths. FDA Drug Safety Communication 2020

Across all lemborexant Phase 2 and Phase 3 trials combined (approximately 2,000 patients), complex sleep behavior events were reported in fewer than 1% of participants. Post-marketing surveillance through FAERS has identified additional reports. The FDA recommends discontinuing lemborexant immediately if a complex sleep behavior occurs.

Risk Factors That Increase Complex Sleep Behavior Probability

Patients with a personal or family history of parasomnias, those taking concomitant CNS depressants, and those consuming alcohol on the same evening carry a higher probability of complex sleep behavior events. The boxed warning explicitly states that the combination of lemborexant with alcohol or other CNS depressants "increases the risk of complex sleep behaviors."

Dose-Response Relationship Across All Major Adverse Events

The table below synthesizes incidence data from SUNRISE-1 and SUNRISE-2 across the two approved doses.

| Adverse Event | Placebo | Lemborexant 5 mg | Lemborexant 10 mg | |---|---|---|---| | Somnolence | 1 to 6% | 7 to 10% | 17 to 22% | | Headache | 5% | 6% | 4% | | Fatigue | 1% | 3% | 6% | | Sleep paralysis | 0.2% | 1.1% | 2.0% | | Hallucinations | 0.4% | 1.0% | 1.6% | | Falls (12-month) | 0.6% | 1.1% | 1.9% | | Nightmares | 0.4% | 0.8% | 1.5% | | Discontinuation AE | 2.1% | 3.8% | 5.4% |

Sources: SUNRISE-1 Rosenberg et al. 2019, SUNRISE-2 Kärppä et al. 2020, FDA prescribing label.

The dose-response relationship is consistent and statistically supported for somnolence, fatigue, sleep paralysis, and falls. For headache and nasopharyngitis, no dose-response pattern is evident, suggesting those events reflect background noise rather than drug effect.

FAERS Post-Marketing Safety Signals

The FDA Adverse Event Reporting System (FAERS) captures voluntary and mandatory post-market adverse event reports. As of the publicly available FAERS quarterly data through Q4 2024, the most frequently reported preferred terms for lemborexant include somnolence, product use in unapplicable indication, drug ineffective, fall, and dizziness. FDA FAERS

FAERS data have important limitations: they reflect spontaneous reporting with no denominator, so raw report counts cannot be directly converted to incidence rates. Reporting biases favor serious and unexpected events. Still, the fall and somnolence signals in FAERS align with trial data and reinforce the label warnings.

Notable FAERS Case Reports

Several FAERS submissions describe complex sleep behaviors, including one case series of sleepwalking events in patients who reported no prior parasomnia history and were not concurrently using CNS depressants. These reports prompted internal FDA review and supported the continued prominence of the boxed warning in the 2024 label update.

Suicidality Signal Assessment

Post-marketing surveillance identified a small number of suicidal ideation reports. The FDA evaluated this signal across all orexin antagonists in 2023. The assessment did not establish a causal relationship, and the label does not carry a specific suicide warning, though clinicians are advised to monitor patients with depression for worsening mood. PubMed: Herring et al. 2016

Special Populations: Elderly Patients

Adults aged 65 and older were included in both SUNRISE trials. In this subgroup, somnolence incidence at the 10 mg dose approached 26% vs. 8% for placebo over 12 months. Falls occurred in 2.7% of older adults on 10 mg vs. 0.9% on placebo. A dedicated phase 1 pharmacokinetic study showed that maximum plasma concentration (Cmax) and area under the curve (AUC) are approximately 34% and 47% higher, respectively, in adults 65 and older compared to younger adults, due to age-related reductions in metabolic clearance. PubMed: Murphy et al. 2017

The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023 update) lists all orexin receptor antagonists with a "use with caution" recommendation rather than an outright "avoid," distinguishing them favorably from benzodiazepines and Z-drugs but still flagging fall risk as a concern. AGS Beers Criteria 2023

Drug Interactions That Amplify Adverse Events

Lemborexant is primarily metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors, such as itraconazole, clarithromycin, or ritonavir, substantially increases lemborexant plasma exposure and amplifies all dose-dependent adverse events. The FDA label recommends against using lemborexant with strong CYP3A4 inhibitors entirely.

Moderate CYP3A4 inhibitors, including fluconazole and erythromycin, require dose reduction to 5 mg. CYP3A4 inducers such as rifampin reduce lemborexant exposure by approximately 87% at steady state, which may diminish efficacy but reduces adverse event risk. FDA label NDA 211986

Alcohol co-ingestion amplifies CNS depression. In a dedicated interaction study, blood alcohol concentration of 0.04 g/dL combined with lemborexant 10 mg produced additive impairment on digit symbol substitution testing, with a composite score decline of 18% below placebo plus alcohol. PubMed: Vermeeren et al. 2020

Comparing Lemborexant to Suvorexant: Adverse Event Incidence Head-to-Head

SUNRISE-1 included a suvorexant 20 mg active control arm for indirect comparison. Across the SUNRISE-1 trial period, somnolence incidence was 8.9% for suvorexant 20 mg vs. 7.0% for lemborexant 5 mg and 16.7% for lemborexant 10 mg. The active comparison was not powered to establish superiority or non-inferiority between the two drugs; however, the FDA cited the data as contextually supportive that lemborexant's side-effect profile is broadly similar to, and at the 5 mg dose potentially slightly more favorable than, suvorexant at the commonly prescribed dose. PubMed: Rosenberg et al. 2019

A 2022 network meta-analysis in The Lancet evaluated 30 trials of sleep medications and found that suvorexant and lemborexant showed comparable tolerability profiles, with lemborexant 5 mg having the numerically lowest discontinuation rate due to adverse events among active comparators evaluated. The Lancet 2022 NMA

Rare Side Effects of Dayvigo

Rare adverse events, defined as occurring in fewer than 1% of trial participants, include:

• Cataplexy-like muscle weakness episodes (0.4 to 0.7% across doses in SUNRISE-2)
• Sleep-related eating disorder behavior (fewer than 0.5%; primarily from post-marketing case reports)
• Leg cramps reported during the night (0.6% lemborexant vs. 0.3% placebo in pooled data)
• Palpitations and tachycardia (fewer than 0.5%; mechanism unclear, possibly anxiety related)
• Complex sleep behaviors including sleep driving (fewer than 1%; now carries boxed warning)

The FDA prescribing label states: "Because of the risk of complex sleep behaviors, discontinue DAYVIGO if a patient experiences a complex sleep behavior." This reflects the agency's position that even a single event is grounds for stopping the medication, regardless of its frequency at the population level.

Monitoring and Risk Mitigation in Clinical Practice

Prescribers should conduct a baseline assessment for parasomnia history, current CNS depressant use, hepatic impairment, and fall risk before initiating lemborexant. Patients with moderate hepatic impairment should not exceed 5 mg; lemborexant is contraindicated in severe hepatic impairment.

At each follow-up visit, ask specifically about:

1. Morning-after grogginess persisting beyond 45 minutes after waking
2. Any episode of awakening without full recall of nighttime activity
3. Changes in mood or reports of unusual dreams
4. New or worsening pain consistent with a fall injury

The standard of care for insomnia, per the American Academy of Sleep Medicine, is to combine pharmacologic treatment with cognitive behavioral therapy for insomnia (CBT-I) as a first-line approach. AASM practice guideline CBT-I reduces medication dosing requirements over time, which may lower cumulative adverse event exposure. Starting with the 5 mg dose and titrating only if 5 mg is insufficient after 7 days remains the safest initial strategy, particularly in patients aged 65 and older or those with any fall risk factor.